Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Inhaled nanobodies against COVID-19


Nanobodies (Nbs) are naturally occurring single-domain antibody fragments from camelid heavy-chain antibodies. They have unique biophysical properties, including small size and thermostability, that allow aerosolized administration. In this preprint, Gai et al. describe Nb phage display libraries from camels immunized with the SARS-CoV-2 spike receptor-binding domain (RBD). Out of 381 Nbs identified, 7 blocked the interaction between the virus entry receptor ACE2 and 8 RBD variants. Nb11-59, a candidate with the highest neutralizing activity, was further selected to validate its interaction with the RBD by structure prediction analysis. Production of Nb11-59 in a yeast expression system followed by its nebulization showed potential for rapid and high-quality manufacturing.


Original article

  1. Gai, J. et al. A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential. Preprint at bioRxiv (2020)

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Gustavo Martinez-Delgado.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Martinez-Delgado, G. Inhaled nanobodies against COVID-19. Nat Rev Immunol 20, 593 (2020).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing